Page 53 - 南京医科大学学报自然科学版
P. 53

第41卷第5期       陆晨妍,龚颖芸,付真真,等. IVGTT过程中血糖及胰岛素急遽波动对血清PCSK9水平的影响[J].
                  2021年5月                     南京医科大学学报(自然科学版),2021,41(05):677-683                       ·683 ·


                    A M. et al. PCSK9 and inflammation:a review of experi⁃  科学版),2019,33(2):259-261
                    mental and clinical evidence[J]. Eur Heart J Cardiovasc  [15] 茅国芳,王坤林,符金香,等. 2 型糖尿病患者血清 PC⁃
                    Pharmacother,2019,5(4):237-245                     SK9与动脉粥样硬化指标的相关性分析[J]. 南京医科
               [4] SPOLITU S,OKAMOTO H,DAI W,ZADROGA J A. et           大学学报(自然科学版),2016,36(1):46-50
                    al. Hepatic glucagon signaling regulates PCSK9 and low⁃  [16] HAMAMURA H,ADACHI H,ENOMOTO M. et al. Se⁃
                    density lipoprotein cholesterol[J]. Circ Res,2019,124  rum proprotein convertase subtilisin/kexin type 9(PC⁃
                    (1):38-51                                          SK9)is independently associated with insulin resistance,
               [5] THEOCHARIDOU E,PAPADEMETRIOU M,REKLOU               triglycerides,lipoprotein(a)levels but not low⁃density li⁃
                    A. et al. The role of PCSK9 in the pathogenesis of non⁃al⁃  poprotein cholesterol levels in a general population[J]. J
                    coholic fatty liver disease and the effect of PCSK9 inhibi⁃
                                                                       Atheroscler Thromb,2020,28(4):329-337
                    tors[J]. Curr Pharm Des,2018,24(31):3654⁃3657
                                                                 [17] MIAO J,MANTHENA P V,HAAS M E. et al. Role of in⁃
               [6] GALLEGO⁃COLON E,DAUM A,YOSEFY C. Statins and
                                                                       sulin in the regulation of proprotein convertase subtilisin/
                    PCSK9 inhibitors:a new lipid⁃lowering therapy[J]. Eur J  kexin type 9 arterioscler[J]. Thromb Vasc Biol,2015,35:
                    Pharmacol,2020,878:173114
                                                                       1589-1596
               [7] FURTADO RHM,GIUGLIANO R P. What lessons have
                                                                 [18] COSTET P,CARIOU B,LAMBERT G. et al. Hepatic PC⁃
                    we learned and what remains to be clarified for PCSK9 in⁃
                                                                       SK9 expression is regulated by nutritional status via insu⁃
                    hibitors? a review of FOURIER and ODYSSEY outcomes
                                                                       lin and sterol regulatory element⁃binding protein 1c[J]. J
                    trials[J]. Cardiol Ther,2020,9(1):59-73
                                                                       Biol Chem,2006,281:6211-6218
               [8] TURGEON R D,TSUYUKI R T,GYENES G T. et al. Car⁃
                                                                 [19] AWAN Z,DUBUC G,FARAJ M. et al. The effect of insu⁃
                    diovascular efficacy and safety of PCSK9 inhibitors:sys⁃
                                                                       lin on circulating PCSK9 in postmenopausal obese women
                    tematic review and meta ⁃ analysis including the ODYS⁃
                                                                      [J]. Clin Biochem,2014,47:1033-1039
                    SEY OUTCOMES trial[J]. Can J Cardiol,2018,34(12):
                                                                 [20]KAPPELLE P J,LAMBERT G,DULLAART R P. Plasma
                    1600-1605
                                                                       proprotein convertase subtilisin ⁃ kexin type 9 does not
               [9] CHEN B,SHI X,CUI Y. et al. A review of PCSK9 inhibi⁃
                                                                       change during 24 h insulin infusion in healthy subjects
                    tors and their effects on cardiovascular diseases[J]. Curr
                                                                       and type 2 diabetic patients[J]. Atherosclerosis,2011,
                    Top Med Chem,2019,19(20):1790-1817
                                                                       214:432-435
               [10] GUO W,GONG Y,GU Y. et al. Circulating PCSK9 levels
                                                                 [21] ZENTI M G,LUPO M G,DE MARTIN S. et al. Impact of
                    and 2⁃hPG are positively correlated in metabolic diseases
                                                                       bariatric surgery⁃induced weight loss on circulating PCSK9
                    in a Chinese Han population[J]. Lipids Health Dis,
                                                                       levels in obese patients[J]. Nutr Metab Cardiovasc Dis,
                    2018,17(15)
                                                                       2020,30(12):2372-2378
               [11] BAASS A,DUBUC G,TREMBLAY M. et al. Plasma PC⁃
                                                                 [22] GREFHORST A,MCNUTT M C,LAGACE T A. et al.
                    SK9 is associated with age,sex,and multiple metabolic
                                                                       Plasma PCSK9 preferentially reduces liver LDL receptors
                    markers in a population⁃based sample of children and ad⁃
                                                                       in mice[J]. J Lipid Res,2008,49:1303-1311
                    olescents[J]. Clin Chem,2009,55:1637-1645
                                                                 [23] GONG Y,MA Y,YE Z. et al. Thyroid stimulating hor⁃
               [12] PETERSEN K S,BOWEN K J,TINDALL A M. et al. The
                                                                       mone exhibits the impact on LDLR/LDL⁃c via up⁃regulat⁃
                    effect of inflammation and insulin resistance on lipid and
                                                                       ing hepatic PCSK9 expression[J]. Metab Clin Exp,2017,
                    lipoprotein responsiveness to dietary intervention[J].
                                                                       76:32-41
                    Curr Dev Nutr,2020,15,4(11):nzaa160
                                                                 [24]LU J,LAM SM,WAN Q. et al. High⁃coverage targeted lip⁃
               [13] MURAKI I. Role of proprotein convertase subtilisin/Kex⁃
                                                                      idomics reveals novel serum lipid predictors and lipid
                    in Type 9(PCSK9)on lipid metabolism and insulin resis⁃
                    tance in Human[J]. J Atheroscler Thromb,2020,28(4):  pathway dysregulation antecedent to type 2 diabetes onset
                                                                      in normoglycemic chinese adults[J]. Diabetes Care,
                    317-318
               [14] 崔   琴,支晓明,郭     雯,等. 体检人群血清PCSK9与代                2019,42:2117-2126
                    谢综合征的相关性分析[J]. 南京医科大学学报(自然                                              [收稿日期] 2021-02-13
   48   49   50   51   52   53   54   55   56   57   58